BI partners two of its antibody candidates with AbbVie
Boehringer Ingelheim GMBH is partnering with AbbVie Inc. on two clinical-stage antibody therapies--anti-IL-23 BI655066 and anti-CD-40 BI655064.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.